ArticleCellular and molecular life sciences : CMLS2026
ZDHHC4-mediated ZEB-2 S-palmitoylation promotes melanoma epithelial-mesenchymal transition via deubiquitinating and stabilizing ZEB-2.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
ZDHHC4, a palmitoyl transferase belonging to the DHHC family, is crucial in cells by catalyzing palmitoylation of proteins, thereby regulating their function and localization. However, its role in melanoma is not well understood. Here, our research determined that ZDHHC4 expression was upregulation in human melanoma specimens and cells. Functional studies reveal that knocking down ZDHHC4 inhibits cell proliferation, migration and invasion of melanoma cells. Moreover, we performed mass spectrometry analysis and found that ZEB-2 is a substrate of ZDHHC4. ZEB-2 interacted with ZDHHC4 through its N-terminal sequences, which promotes the ZDHHC4-mediated palmitoylation of ZEB-2 at C478, facilitating ZEB-2 deubiquitination and its protein stability. This key modification is required for epithelial-to-mesenchymal transition (EMT) in melanoma cells. Furthermore, we found a positive correlation between the expression levels of ZDHHC4 and ZEB-2 in clinical melanoma samples. In summary, our results provide a deeper understanding of mechanism regulating ZDHHC4 in melanoma, suggesting that targeting ZDHHC4 may offer novel therapeutic strategies by suppressing tumor growth and metastasis through the disruption of ZEB-2 palmitoylation process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.